Literature DB >> 28198350

Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.

Ilaria Motta1, Tiziano Allice2, Alessandra Romito3, Micol Ferrara1, Sara Ecclesia1, Daniele Imperiale4, Valeria Ghisetti2, Giovanni Di Perri1, Stefano Bonora1, Andrea Calcagno1.   

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) HIV RNA is commonly used as a marker of compartmental antiviral activity in HIV-positive patients. Undetectable CSF HIV RNA levels have been associated with low CSF neopterin levels and better neurocognitive performances. The aim of this study was to analyse the prevalence and predictors of non-detectable CSF HIV RNA using a commercial assay.
METHODS: In adult HIV-positive HAART-treated patients with confirmed plasma HIV RNA <50 copies/ml, CSF HIV RNA (with Roche Amplicor Assay) and neopterin were measured.
RESULTS: 112 adult patients were included. Plasma and CSF HIV RNA were non-detectable (target not detected [TND]) in 29 (25.9%) and 36 (32.1%) patients, respectively. CSF TND was observed more frequently in patients with plasma TND (P=0.005, OR=3.87). CSF neopterin levels were associated with age (rho =0.333, P=0.002) and current (rho= -0.272, P=0.015) and nadir (rho =-0.240, P=0.038) CD4+ T-lymphocytes; the lowest CSF neopterin concentration was observed in patients with CSF TND versus other viral load strata (0.62 mg/dl versus 0.78 mg/dl; P=0.048).
CONCLUSIONS: Efficaciously treated HIV-positive patients with detectable plasma HIV RNA might imperfectly control CSF viral replication. Prospective studies addressing the management and neurocognitive consequences of CSF low-level viraemia are warranted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28198350     DOI: 10.3851/IMP3140

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  6 in total

1.  Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis.

Authors:  V Fominykh; L Brylev; V Gaskin; R Luzin; A Yakovlev; I Komoltsev; I Belousova; A Rosliakova; A Guekht; N Gulyaeva
Journal:  Metab Brain Dis       Date:  2019-07-02       Impact factor: 3.584

Review 2.  CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.

Authors:  Andrea Calcagno; Ambra Barco; Mattia Trunfio; Stefano Bonora
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

3.  Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART).

Authors:  E Merlini; F Iannuzzi; A Calcagno; F Bai; M Trunfio; A d'Arminio Monforte; S Bonora; Giulia Marchetti
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

4.  Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders.

Authors:  A Barco; S Orlando; G Stroffolini; V Pirriatore; A Lazzaro; D Vai; G Guastamacchia; G Noce; C Atzori; M Trunfio; S Bonora; G Di Perri; A Calcagno
Journal:  J Neurovirol       Date:  2022-01-19       Impact factor: 2.643

5.  Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation.

Authors:  Tommaso Lupia; Maria Grazia Milia; Cristiana Atzori; Sara Gianella; Sabrina Audagnotto; Daniele Imperiale; Lorenzo Mighetto; Veronica Pirriatore; Gabriella Gregori; Filippo Lipani; Valeria Ghisetti; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  AIDS       Date:  2020-03-01       Impact factor: 4.632

6.  Markers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL.

Authors:  Shelli F Farhadian; Hetal Mistry; Tobias Kirchwey; Jennifer Chiarella; Rachela Calvi; Michelle Chintanaphol; Payal Patel; Marie L Landry; Kevin Robertson; Serena S Spudich
Journal:  Open Forum Infect Dis       Date:  2019-12-14       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.